Novartis AG

More Details of Novartis AG Company

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Company Info

Company codeNVS

Company nameNovartis AG

IPO dateMay 07, 2001

Founded at1996

CEODr. Vasant (Vas) Narasimhan, M.D.

Number of employees75883

Security typeOrdinary Share

Fiscal year-endMay 07

AddressLichtstrasse 35

CityBASEL

Stock exchangeJohannesburg Stock Exchange

CountrySwitzerland

Postal code4056

Phone41613241111

Websitehttps://www.novartis.com/

Company codeNVS

IPO dateMay 07, 2001

Founded at1996

Company Executives

Name

Name/Position

Position

Shareholding

Change

Ms. Elizabeth (Liz) Doherty

Non-Executive Independent Director

--

Mr. Ton Buechner

Non-Executive Independent Director

--

Mr. Aaron (Ronny) Gal, Ph.D.

Chief Strategy and Growth Officer, Member of the Executive Committee

--

Mr. Victor Bulto

President - US, Member of the Executive Committee

--

Ms. Charlotte Pamer- Wieser, Ph.D.

Corporate Secretary

--

Ms. Karen L. Hale

Chief Legal Officer, Member of the Executive Committee

--

Mr. Frans van Houten

Non-Executive Independent Director

--

Ms. Elizabeth Mcnally

Director

--

Dr. Steffen Lang, Ph.D.

President - Operations, Member of the Executive Committee

--

Mr. Harry Kirsch

Chief Financial Officer, Member of the Executive Committee

--

Name

Name/Position

Position

Shareholding

Change

Ms. Elizabeth (Liz) Doherty

Non-Executive Independent Director

--

Mr. Ton Buechner

Non-Executive Independent Director

--

Mr. Aaron (Ronny) Gal, Ph.D.

Chief Strategy and Growth Officer, Member of the Executive Committee

--

Mr. Victor Bulto

President - US, Member of the Executive Committee

--

Ms. Charlotte Pamer- Wieser, Ph.D.

Corporate Secretary

--

Ms. Karen L. Hale

Chief Legal Officer, Member of the Executive Committee

--

Revenue Breakdown

Currency: USDUpdate time: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Rest of portfolio

10.07B

20.02%

Cardiovascular, Renal and Metabolism - Entresto

7.82B

15.55%

Immunology - Cosentyx

6.14B

12.20%

Neuroscience - Kesimpta

3.22B

6.41%

Oncology -Kisqali

3.03B

6.03%

Other

20.02B

39.80%

By RegionUSD

Name

Revenue

Proportion

United States

21.15B

42.03%

Other Foreign-

18.51B

36.79%

China

3.89B

7.73%

Germany

3.66B

7.27%

France

1.79B

3.56%

Switzerland

1.31B

2.61%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Rest of portfolio

10.07B

20.02%

Cardiovascular, Renal and Metabolism - Entresto

7.82B

15.55%

Immunology - Cosentyx

6.14B

12.20%

Neuroscience - Kesimpta

3.22B

6.41%

Oncology -Kisqali

3.03B

6.03%

Other

20.02B

39.80%

Shareholder

Update time: Wed, Apr 30

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

Dodge & Cox

0.62%

PRIMECAP Management Company

0.56%

Dimensional Fund Advisors, L.P.

0.41%

Loomis, Sayles & Company, L.P.

0.28%

Franklin Mutual Advisers, LLC

0.22%

Other

97.91%

Shareholder Statistics

Shareholder

Proportion

Dodge & Cox

0.62%

PRIMECAP Management Company

0.56%

Dimensional Fund Advisors, L.P.

0.41%

Loomis, Sayles & Company, L.P.

0.28%

Franklin Mutual Advisers, LLC

0.22%

Other

97.91%

Type

Shareholder

Proportion

Investment Advisor

3.25%

Investment Advisor/Hedge Fund

2.63%

Research Firm

0.34%

Hedge Fund

0.28%

Bank and Trust

0.12%

Pension Fund

0.03%

Family Office

0.01%

Other

93.34%

Institutional Shareholding

Update time: Thu, Feb 20

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

1909

132.57M

6.71%

-9.01M

2024Q4

1926

134.00M

6.78%

-9.24M

2024Q3

1858

134.89M

6.74%

-11.71M

2024Q2

1840

139.20M

6.87%

-9.16M

2024Q1

1808

141.30M

6.92%

-7.93M

2023Q4

1811

141.99M

6.94%

-15.97M

2023Q3

1775

150.92M

7.33%

-7.18M

2023Q2

1759

150.74M

7.28%

-24.15M

2023Q1

1762

167.49M

7.98%

-13.01M

2022Q4

1782

173.67M

8.19%

-17.15M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

Dodge & Cox

12.21M

0.62%

-7.21K

-0.06%

Dec 31, 2024

PRIMECAP Management Company

11.03M

0.56%

-983.02K

-8.19%

Dec 31, 2024

Dimensional Fund Advisors, L.P.

8.18M

0.41%

+90.82K

+1.12%

Dec 31, 2024

Loomis, Sayles & Company, L.P.

5.58M

0.28%

-192.68K

-3.34%

Dec 31, 2024

Franklin Mutual Advisers, LLC

4.26M

0.22%

-16.98K

-0.40%

Dec 31, 2024

Wellington Management Company, LLP

3.65M

0.18%

-351.31K

-8.78%

Dec 31, 2024

Morgan Stanley Smith Barney LLC

3.59M

0.18%

-52.88K

-1.45%

Dec 31, 2024

Parametric Portfolio Associates LLC

2.98M

0.15%

-86.17K

-2.81%

Dec 31, 2024

Managed Account Advisors LLC

2.95M

0.15%

-214.17K

-6.76%

Dec 31, 2024

Renaissance Technologies LLC

2.67M

0.14%

+368.17K

+16.00%

Dec 31, 2024

Related ETFs

Update time: Sun, Apr 6

Name

Proportion

VanEck Pharmaceutical ETF

5.37%

Cullen Enhanced Equity Income ETF

4.16%

Invesco International Dividend Achievers ETF

2.69%

Amplify International Enhanced Dividend Income ETF

2.67%

Altrius Global Dividend ETF

2.35%

SGI Enhanced Global Income ETF

2.07%

Pacer Global Cash Cows Dividend ETF

2.06%

Abacus FCF International Leaders ETF

1.9%

SP Funds S&P World (ex-US) ETF

1.78%

The Opal International Dividend Income ETF

1.74%

VanEck Pharmaceutical ETF

Proportion5.37%

Cullen Enhanced Equity Income ETF

Proportion4.16%

Invesco International Dividend Achievers ETF

Proportion2.69%

Amplify International Enhanced Dividend Income ETF

Proportion2.67%

Altrius Global Dividend ETF

Proportion2.35%

SGI Enhanced Global Income ETF

Proportion2.07%

Pacer Global Cash Cows Dividend ETF

Proportion2.06%

Abacus FCF International Leaders ETF

Proportion1.9%

SP Funds S&P World (ex-US) ETF

Proportion1.78%

The Opal International Dividend Income ETF

Proportion1.74%

Dividend

A total of 36.74B USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Feb 20, 2025

NVS.NB Approximate final Cash Dividend of gross USD 3.869541 going ex on Mar 12, 2025

Mar 12, 2025

May 01, 2025

Mar 12, 2025

Feb 12, 2024

NVS.NB Final Cash Dividend of gross USD 3.739544 paid on Apr 19, 2024 going ex on Mar 07, 2024

Mar 08, 2024

Apr 19, 2024

Mar 07, 2024

Feb 02, 2023

NVS.NB Final Cash Dividend of gross USD 3.498699 paid on Mar 20, 2023 going ex on Mar 09, 2023

Mar 10, 2023

Mar 20, 2023

Mar 09, 2023

Feb 04, 2022

NVS.NB Final Cash Dividend of gross USD 3.32525 paid on Mar 17, 2022 going ex on Mar 08, 2022

Mar 09, 2022

Mar 17, 2022

Mar 08, 2022

Jan 26, 2021

NVS.NB Final Cash Dividend of gross USD 3.199072 paid on Mar 15, 2021 going ex on Mar 04, 2021

Mar 05, 2021

Mar 15, 2021

Mar 04, 2021

Jan 31, 2020

NVS.NB Final Cash Dividend of gross USD 3.087366 paid on Mar 12, 2020 going ex on Mar 03, 2020

Mar 04, 2020

Mar 12, 2020

Mar 03, 2020

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

113.400USD

Novartis AG

113.400

Overview

Company